GSA Capital Partners LLP reduced its position in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Free Report) by 42.0% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 37,662 shares of the company’s stock after selling 27,220 shares during the period. GSA Capital Partners LLP owned 0.07% of 4D Molecular Therapeutics worth $407,000 at the end of the most recent reporting period.
Several other large investors have also modified their holdings of FDMT. nVerses Capital LLC acquired a new stake in shares of 4D Molecular Therapeutics during the 3rd quarter worth about $40,000. Values First Advisors Inc. acquired a new stake in 4D Molecular Therapeutics in the 3rd quarter valued at about $57,000. Quest Partners LLC increased its position in 4D Molecular Therapeutics by 17,409.1% in the 2nd quarter. Quest Partners LLC now owns 5,778 shares of the company’s stock valued at $121,000 after acquiring an additional 5,745 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its position in 4D Molecular Therapeutics by 64.6% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,995 shares of the company’s stock valued at $108,000 after acquiring an additional 3,922 shares in the last quarter. Finally, Proficio Capital Partners LLC acquired a new stake in 4D Molecular Therapeutics in the 3rd quarter valued at about $108,000. 99.27% of the stock is owned by institutional investors.
4D Molecular Therapeutics Stock Performance
Shares of FDMT stock opened at $7.99 on Friday. The firm has a market capitalization of $369.38 million, a PE ratio of -2.80 and a beta of 2.82. The stock has a fifty day simple moving average of $9.72 and a two-hundred day simple moving average of $16.66. 4D Molecular Therapeutics, Inc. has a 52-week low of $7.32 and a 52-week high of $36.25.
Wall Street Analysts Forecast Growth
View Our Latest Stock Report on 4D Molecular Therapeutics
4D Molecular Therapeutics Company Profile
4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.
Recommended Stories
- Five stocks we like better than 4D Molecular Therapeutics
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Why Palo Alto Networks’ Multi-Year Uptrend Is Far From Over
- Ride Out The Recession With These Dividend KingsĀ
- 3 Rock-Solid Buying Opportunities in the Market Right Now
- How to Invest in the FAANG Stocks
- TJX Companies Stock Poised to Hit a New High This Year
Want to see what other hedge funds are holding FDMT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Free Report).
Receive News & Ratings for 4D Molecular Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 4D Molecular Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.